-
Xinhua Pharmaceutical Lactic Acid Bacteria Granules Obtained Drug Registration Certificate from NMPA
Time of Update: 2021-03-22
Lactic acid bacteria granules are over-the-counter drugs.
Lactobacillus is a class of peptides, proteins or protein complexes with antibacterial activity produced by lactic acid bacteria through ribosome synthesis mechanism in the metabolic process after skimmed milk is fermented.
-
Merck's oral selective P2X3 receptor antagonist gefapixant enters review in the U.S.
Time of Update: 2021-03-22
041); (2) In the COUGH-2 study, at the 24th week of treatment, compared with the placebo group, the 24-hour cough frequency of the 45 mg dose of gefapixant twice a day was significantly reduced by 14.
-
2020 Health Care Development Statistics Express
Time of Update: 2021-03-22
8%。 （） The total income and total expenditures of the basic medical insurance fund (including maternity insurance) for the year were 2.
The income from the basic medical insurance fund (including maternity insurance) for employees in the whole year was 1,562.
-
How can biopharmaceons innovate and purchase more for the good of the country and the people in the new era?
Time of Update: 2021-03-22
Innovative procurement policies need to pay attention to the particularity of biological products, and fully consider the "three characteristics" of specific products (similarity of biosimilars, stability of production and supply, and clinical substitutability) to formulate appropriate policies to ensure the safety of patients' medications and promote The healthy development of the industry.
-
China Biopharmaceuticals won the ANDA!
Time of Update: 2021-03-22
At present, there are three domestic manufacturers of fosapitan and dimeglumine for injection: Jiangsu Haosen Pharmaceutical, Zhengda Tianqing Pharmaceutical Group, and Qilu Pharmaceutical.
-
Top 10 patent expired drugs in 2021: 3 have entered China involving ranibizumab and sunitinib
Time of Update: 2021-03-22
S. in 2020: Undisclosed ($600 million in sales in 2019)Indications: HypertensionPotential generic drug entry: September 17, 2021When AbbVie signed its Allergan large-scale acquisition plan in 2019, the company tried to consolidate its future after Xiumira.
-
Top 10 drugs that lose patent rights in the U.S. market in 2021
Time of Update: 2021-03-22
S. sales in 2020: undisclosed (2019 sales of $600 million)Disease: HypertensionGeneric drugs enter the market: September 17Bystolic, approved for the treatment of high blood pressure, lost the protection of its last patent on December 17 this year.
-
Successful Phase II proof-of-concept study of GlaxoSmithKline's first in class AIDS drug
Time of Update: 2021-03-22
The Phase IIa study adopted an adaptive design and included two phases to evaluate the antiviral activity, safety, and tolerability of GSK3640254 once a day in 34 untreated adult HIV-1 infected patients.
-
The top 5 best-selling gout drugs in pharmacies exposed to the first "siege"
Time of Update: 2021-03-22
Sales of terminal anti-gout preparations in physical pharmacies in cities in China Source: Mi Nei. com, China's urban physical pharmacy terminal competition pattern In recent years, the market scale of terminal anti-gout preparations in Chinese urban physical pharmacies has been expanding, and the annual growth rate has remained at double digits.
-
Our country's fight against poverty has won an all-round victory!
Time of Update: 2021-03-22
As of the end of 2020, the medical insurance and poverty alleviation policies have benefited 530 million people from the poor, reducing the burden of medical expenses of the poor by more than 360 billion yuan (2020 National Basic Medical Insurance Fund for the current period) The balance is about 270 billion yuan).
-
Two Sessions Topics | Ke Yunfeng's voice affects 520,000 pharmacies
Time of Update: 2021-03-22
Attachment: Suggestions on the revision of the "Anti-Unfair Competition Law"The country has been encouraging the development of the Internet and platform economy for many years.
The revision of the "Anti-Unfair Competition Law" is conducive to establishing a correct understanding of the real economy and platform economy and the need for top-level design.
-
Large hospitals have entered the era of one hospital with multiple districts!
Time of Update: 2021-03-22
The recent meeting of the Central Deep Reform Commission made it clear that it is necessary to accelerate the expansion of high-quality medical resources and the balanced distribution of regions, which is considered to be the fundamental guideline for the development of multiple districts in one hospital.
-
In 2021, 69 UDI categories in 9 categories will be promoted globally
Time of Update: 2021-03-22
69 varieties in 9 categories have landed In the field of production, the Food and Drug Administration of Fujian Province pointed out that the country’s first batch of 69 varieties of 9 categories of unique medical device identification has been officially implemented.
-
Government Work Report: Health Care Reform, Collection, Antitrust...
Time of Update: 2021-03-22
39 35，，，，“”“”。，，，，，，，，、，。 2020 ：。，“”，“”，，、。，，“”，。，，。，，2. 6，1. 7。，2，，。，，50%，1. 5。“”。，，，2. 3%，，。 ，。，。，。，。1186，5. 2%。，，。，2. 5%。、、。。，、600，800。 ，。。，。，，。，。。551、52。 ，。。“”，。。。。、。“”。。。，。 ，。，。。，，。，。 ，。。
-
[Attention] The third domestic product!
Time of Update: 2021-03-22
Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with the imitation of sunitinib malate capsules for production of category 4, and it is expected to be approved in the near future, sprinting into the third domestic market.
-
Special purchase with quantity is coming
Time of Update: 2021-03-22
cn/news/yyzb/" target="_blank"> Procurement Procurement Centralized procurement and renewal time summary (Drawing: Fengyun Medicine Talk) Although the fifth batch of national centralized procurement and special volume procurement in 2021 are the focus of the industry, for pharmaceutical companies, the renewal of centralized procurement is also a top priority.
-
New target IL-36R, a new drug for psoriasis, a phase II study failed
Time of Update: 2021-03-22
On March 8, AnaptysBio announced that the top-line data of the phase II clinical study (POPLAR) of the anti-IL-36R monoclonal antibody imsidolimab for the treatment of moderate to severe palmoplantar pustulosis (PPP) did not meet the primary endpoint.
-
Important speech at the two sessions!
Time of Update: 2021-03-22
Xi Jinping emphasized that at the critical moment of the fight against the new crown pneumonia epidemic, the majority of medical workers have lived up to the trust of the party and the people.
-
Huadong Medicine MB-102 injection clinical trial application was accepted
Time of Update: 2021-03-22
On March 9th, Huadong Medicine issued an announcement stating that its wholly-owned subsidiary Sino-American Huadong received the "Notice of Acceptance" approved and issued by NMPA, and the applicatio
-
The country is about to start special insulin procurement! The second batch of centralized procurement of medicines in six provinces and two districts is about to start
Time of Update: 2021-03-22
According to the news received late at night last night, Nanjing’s main topics are four:The country will carry out special procurement with quantities, and the first batch of test water varieties will be insulin.
